Home-based urinary sodium monitoring via point-of-care testing for personalized diuretic titration in heart failure management: The EASY-STOP study
- PMID: 40389240
- DOI: 10.1002/ejhf.3693
Home-based urinary sodium monitoring via point-of-care testing for personalized diuretic titration in heart failure management: The EASY-STOP study
Abstract
Aims: Loop diuretics alleviate symptoms in heart failure (HF), but despite recommendations for dynamic dosing, implementation in practice remains challenging. The EASY-STOP trial investigated whether ambulatory urinary sodium monitoring using a point-of-care sensor could guide diuretic down-titration.
Methods and results: This prospective, single-centre study enrolled 50 euvolaemic HF patients on stable guideline-directed medical therapy for ≥3 months and receiving maintenance loop diuretic (≥20 mg furosemide equivalent daily). After a 1-week baseline phase of daily self-measured first-void and post-diuretic urinary sodium assessment, loop diuretics were gradually reduced by 50% and discontinued when ≤20 mg furosemide equivalents. Urinary monitoring continued for another 3 weeks. Successful down-titration was defined as remaining congestion-free (no rise in New York Heart Association class ≥I, oedema, pleural effusion, ascites, rise in right ventricular systolic pressure ≥10 mmHg, or worsening diastolic dysfunction ≥1 grade). Investigators and patients were blinded for urinary sodium analysis during the study. Patients were 75 (68-79) years old, had left ventricular ejection fraction 46 (± 11)%, estimated glomerular filtration rate 47 (35-65) ml/min and N-terminal pro-B-type natriuretic peptide 899 (326-2558) ng/L. Among the 50 patients, 62 diuretic down-titrations were performed, of which 34 (55%) were successful. Baseline urinary sodium before loop diuretic down-titration was similar between groups. However, patients who successfully achieved down-titration exhibited a significant increase in first-void urinary sodium following down-titration (53-74 mmol/L, p < 0.001), whereas those requiring reinitiation showed no significant change (56-58 mmol/L, p = 0.331). A 10 mmol/L increase predicted successful down-titration with 79.4% sensitivity and 78.6% specificity (area under the curve = 0.851).
Conclusions: Point-of-care urinary sodium monitoring may represent a non-invasive and personalized approach to diuretic titration in HF management. Further trials are warranted to validate its clinical utility and long-term benefits.
Keywords: Heart failure; Loop diuretics; Natriuresis.
© 2025 European Society of Cardiology.
Similar articles
-
Continuous infusion versus bolus injection of loop diuretics for acute heart failure.Cochrane Database Syst Rev. 2024 May 22;5(5):CD014811. doi: 10.1002/14651858.CD014811.pub2. Cochrane Database Syst Rev. 2024. PMID: 38775253 Free PMC article.
-
Serial direct sodium removal in patients with heart failure and diuretic resistance.Eur J Heart Fail. 2024 May;26(5):1215-1230. doi: 10.1002/ejhf.3196. Epub 2024 Mar 31. Eur J Heart Fail. 2024. PMID: 38556717 Clinical Trial.
-
Salt repletion and diuretic response: The role of serum chloride. A post-hoc analysis of the SALT-HF trial on furosemide and hypertonic saline solution administration in ambulatory patients with worsening heart failure.Eur J Heart Fail. 2025 Jun;27(6):960-971. doi: 10.1002/ejhf.3597. Epub 2025 Feb 11. Eur J Heart Fail. 2025. PMID: 39933832 Clinical Trial.
-
Diuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: The TRANSFORM-HF trial.Eur J Heart Fail. 2025 Feb;27(2):317-324. doi: 10.1002/ejhf.3458. Epub 2024 Oct 4. Eur J Heart Fail. 2025. PMID: 39363809 Clinical Trial.
-
The Black Book of Psychotropic Dosing and Monitoring.Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
References
-
- Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, et al. The global health and economic burden of hospitalizations for heart failure: Lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 2014;63:1123–1133. https://doi.org/10.1016/j.jacc.2013.11.053
-
- McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022;24:4–131. https://doi.org/10.1002/ejhf.2333
-
- McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al.; PARADIGM‐HF Investigators and Committees. Angiotensin‐neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371(11):993–1004. https://doi.org/10.1056/NEJMoa1409077
-
- Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al.; EMPEROR‐Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385(16):1451–1461. https://doi.org/10.1056/NEJMoa2107038
-
- Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al.; EMPEROR‐Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383(15):1413–1424. https://doi.org/10.1056/NEJMoa2022190
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous